{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T19:52:27Z","timestamp":1780602747609,"version":"3.54.1"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T00:00:00Z","timestamp":1741824000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Checkpoint blockade therapy (CBT) involving anti-PD1 antibodies represents the standard approach for cHL patients who do not respond to second-line therapy. Nonetheless, only 20% of relapsed\/refractory (R\/R) cHL patients treated with CBT achieve complete remission. In this study, we extensively examined the immune dynamics in eight R\/R cHL patients treated with CBT, consisting of four complete responders (CR) and four experiencing disease progression (PD), by single cell analysis of peripheral blood mononuclear cells (PBMCs). Our unique approach encompassed longitudinal analysis with three time points, providing a comprehensive understanding of the evolving immune responses during anti-PD1 therapy. Through gene expression profiling, we identified a stable and distinctive KLRG1+\/FOS+\/JUN+\/GZMA+\/CD8+ T cell phenotype in patients achieving complete responses. This specific CD8+ T cell subset exhibited sustained activation, underscoring its potential pivotal role in mounting an effective immune response against cHL. Furthermore, T cell receptor (TCR) analysis revealed that in responder patients there is clonal expansion between TCR clonotypes specifically in the KLRG1+\/FOS+\/JUN+\/GZMA+\/CD8+ T cell subset. Our longitudinal study offers unique insights into the complex immune dynamics of multiply relapsed\/highly pre-treated cHL patients undergoing anti-PD1 therapy.<\/jats:p>","DOI":"10.3389\/fonc.2025.1518107","type":"journal-article","created":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T03:03:54Z","timestamp":1741835034000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["The immune cell dynamics in the peripheral blood of cHL patients receiving anti-PD1 treatment"],"prefix":"10.3389","volume":"15","author":[{"given":"Vanessa","family":"Cristaldi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lodovico","family":"Terzi di Bergamo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucrezia","family":"Patruno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marinos","family":"Kallikourdis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giada Andrea","family":"Cassanmagnago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Corrado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Calabretta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adalgisa","family":"Condoluci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"di Trani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daoud","family":"Rahal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Basso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clelia","family":"Peano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Graudenzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Antoniotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmelo","family":"Carlo-Stella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01204-6","article-title":"Molecular biology of Hodgkin lymphoma","volume":"35","author":"Weniger","year":"2021","journal-title":"Leukemia"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06903-x","article-title":"Distinct Hodgkin lymphoma subtypes defined by noninvasive genomic profiling","volume":"625","author":"Alig","year":"2024","journal-title":"Nature"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.3390\/cancers14051360","article-title":"The hodgkin lymphoma immune microenvironment: turning bad news into good","volume":"14","author":"Men\u00e9ndez","year":"2022","journal-title":"Cancers"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022017147","article-title":"Novel insights into Hodgkin lymphoma biology by single-cell analysis","volume":"141","author":"Aoki","year":"2023","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2019.09.030","article-title":"Mechanisms controlling PD-L1 expression in cancer","volume":"76","author":"Cha","year":"2019","journal-title":"Mol Cell"},{"key":"B6","doi-asserted-by":"publisher","first-page":"4665","DOI":"10.3390\/jcm10204665","article-title":"Hodgkin lymphoma: A special microenvironment","volume":"10","author":"Opinto","year":"2021","journal-title":"JCM"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/labinvest.2008.24","article-title":"The CD4+CD26\u2013 T-cell population in classical Hodgkin\u2019s lymphoma displays a distinctive regulatory T-cell profile","volume":"88","author":"Ma","year":"2008","journal-title":"Lab Invest"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2033433","DOI":"10.1080\/2162402X.2022.2033433","article-title":"CD4+ T cells in classical Hodgkin lymphoma express exhaustion associated transcription factors TOX and TOX2: Characterizing CD4+ T cells in Hodgkin lymphoma","volume":"11","author":"Veldman","year":"2022","journal-title":"OncoImmunology"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.586907","article-title":"Systemic CD4 immunity as a key contributor to PD-L1\/PD-1 blockade immunotherapy efficacy","volume":"11","author":"Zuazo","year":"2020","journal-title":"Front Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.943354","article-title":"Regulatory T cells (Tregs) in lymphoid Malignancies and the impact of novel therapies","volume":"13","author":"Maharaj","year":"2022","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-04-843714","article-title":"Mass cytometry of Hodgkin lymphoma reveals a CD4+ regulatory T-cell\u2013rich and exhausted T-effector microenvironment","volume":"132","author":"Cader","year":"2018","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti\u2013PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti\u2013PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory hodgkin\u2019s lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.3467","article-title":"Programmed death-1 blockade with pembrolizumab in patients with classical hodgkin lymphoma after brentuximab vedotin failure","volume":"34","author":"Armand","year":"2016","journal-title":"JCO"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01597","article-title":"PD-1\/PD-L1 blockade: have we found the key to unleash the antitumor immune response","volume":"8","author":"Xu-Monette","year":"2017","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1001\/jamaoncol.2022.7975","article-title":"Pembrolizumab added to ifosfamide, carboplatin, and etoposide chemotherapy for relapsed or refractory classic hodgkin lymphoma: A multi-institutional phase 2 investigator-initiated nonrandomized clinical trial","volume":"9","author":"Bryan","year":"2023","journal-title":"JAMA Oncol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/bjh.v198.1","article-title":"Chemotherapy after PD -1 inhibitors in relapsed\/refractory Hodgkin lymphoma: Outcomes and clonal evolution dynamics","volume":"198","author":"Calabretta","year":"2022","journal-title":"Br J Haematol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1200\/OP.20.00771","article-title":"Checkpoint inhibition therapy in transplant-ineligible relapsed or refractory classic hodgkin lymphoma","volume":"17","author":"Al-Hadidi","year":"2021","journal-title":"JCO Oncol Pract"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1397053","article-title":"Immune checkpoint inhibitors in advanced and relapsed\/refractory Hodgkin lymphoma: current applications and future prospects","volume":"14","author":"Milrod","year":"2024","journal-title":"Front Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-018-0071-8","article-title":"Single-cell RNA sequencing technologies and bioinformatics pipelines","volume":"50","author":"Hwang","year":"2018","journal-title":"Exp Mol Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-019-0544-5","article-title":"TCR sequencing paired with massively parallel 3\u2032 RNA-seq reveals clonotypic T cell signatures","volume":"20","author":"Tu","year":"2019","journal-title":"Nat Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.0793","article-title":"Nivolumab for relapsed\/refractory classic hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II checkMate 205 trial","volume":"36","author":"Armand","year":"2018","journal-title":"JCO"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of hodgkin and non-hodgkin lymphoma: the lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"JCO"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World medical association declaration of helsinki: ethical principles for medical research involving human subjects","volume":"310","year":"2013","journal-title":"JAMA"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without","volume":"372","author":"Robert","year":"2015","journal-title":"BRAF Mutation. N Engl J Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nbt.3192","article-title":"Spatial reconstruction of single-cell gene expression data","volume":"33","author":"Satija","year":"2015","journal-title":"Nat Biotechnol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btaa611","article-title":"Scirpy: a Scanpy extension for analyzing single-cell T-cell receptor-sequencing data","volume":"36","author":"Sturm","year":"2020","journal-title":"Bioinformatics"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30167-X","article-title":"Nivolumab for classical Hodgkin\u2019s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial","volume":"17","author":"Younes","year":"2016","journal-title":"Lancet Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2018.8957","article-title":"Elucidating feed\u2212forward apoptosis signatures in breast cancer datasets: Higher FOS expression associated with a better outcome","author":"Fisler","year":"2018","journal-title":"Oncol Lett"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2007.07.010","article-title":"Inflammation directs memory precursor and short-lived effector CD8+ T cell fates via the graded expression of T-bet transcription factor","volume":"27","author":"Joshi","year":"2007","journal-title":"Immunity"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1901512","article-title":"KLRG1+ Memory CD8 T cells combine properties of short-lived effectors and long-lived memory","volume":"205","author":"Renkema","year":"2020","journal-title":"J Immunol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"2470","DOI":"10.3390\/cells9112470","article-title":"The Multifaceted Output of c-Jun Biological Activity: Focus at the Junction of CD8 T Cell Activation and Exhaustion","volume":"9","author":"Papavassiliou","year":"2020","journal-title":"Cells"},{"key":"B34","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/S1074-7613(00)80059-X","article-title":"Granzyme A initiates an alternative pathway for granule-mediated apoptosis","volume":"10","author":"Shresta","year":"1999","journal-title":"Immunity"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.00017","article-title":"T cell dysfunction and exhaustion in cancer","volume":"8","author":"Zhang","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-019-0022-x","article-title":"Immune awakening revealed by peripheral T cell dynamics after one cycle of immunotherapy","volume":"1","author":"Valpione","year":"2020","journal-title":"Nat Cancer"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-1006-1","article-title":"A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin lymphoma","volume":"26","author":"Cader","year":"2020","journal-title":"Nat Med"},{"key":"B38","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1158\/2326-6066.CIR-23-0547","article-title":"Repertoire, and function in classical hodgkin lymphoma revealed through single-cell analyses","volume":"12","author":"Chen","year":"2024","journal-title":"Cancer Immunol Res"},{"key":"B39","doi-asserted-by":"publisher","first-page":"5487","DOI":"10.3390\/cancers13215487","article-title":"CD8+ T lymphocytes immune depletion and LAG-3 overexpression in hodgkin lymphoma tumor microenvironment exposed to anti-PD-1 immunotherapy","volume":"13","author":"Michot","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008553","article-title":"Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1","volume":"136","author":"Reinke","year":"2020","journal-title":"Blood"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1518107\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T03:03:59Z","timestamp":1741835039000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1518107\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,13]]},"references-count":40,"alternative-id":["10.3389\/fonc.2025.1518107"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1518107","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.05.15.24307370","asserted-by":"object"}]},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,13]]},"article-number":"1518107"}}